Article metrics

  • citations in SCindeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[=>]
  • visits in previous 30 days:4
  • full-text downloads in 30 days:4
article: 2 from 12  
Back back to result list
Medicinski podmladak
2019, vol. 70, iss. 1, pp. 48-52
article language: English
document type: Original Scientific Paper
published on: 24/05/2019
doi: 10.5937/mp70-17921
Creative Commons License 4.0
Risk assessment for the development of metabolic syndrome in patients with AIDS, after the first year of antiretroviral therapy
aUniversity of Kragujevac, Faculty of Medicine
bUniversity of Kragujevac, Faculty of Medicine



Introduction: Antiretroviral therapy (ART) in the treatment of HIV infection has allowed maximum control of viral replication and reconstruction of the immune system, which has contributed to the long-term survival. However, it has been observed that a long-term use of ART can lead to cumulative toxicity and metabolic abnormalities. Aim: the aim of this study was to determine whether there is a difference in lipidogram, glycemia and body mass index (BMI) before and after the initiation of ART, and to determine in which of the antiretroviral drugs the changes in the values of the measured variables were most common. Material and methods: the research was conducted at the Clinic for Infectious Diseases, Clinical Center of Kragujevac, as a prospective study involving 40 patients diagnosed with HIV infection. Biochemical parameters and BMI calculation were performed before the initiation of ART and one year after. Results: the analysis of the observed variables indicated a statistically significant difference in total cholesterol (p = 0.001), HDL (p = 0.002), LDL (p = 0.003), triglycerides (p < 0.001), glucose (p < 0.001) and BMI (p = 0.002). By analyzing the administered АRT therapy, statistical significance was achieved in the measured triglyceride values after the administration of ritonavir and lopinavir, while the highest BMI values, compared to initial ones, were observed after the administration of ritonavir, but without achieving statistical significance. Conclusion: the results of the study showed that АRТ therapy has effect on the development of hyperlipidemia, which may be associated with an increased risk of developing cardiovascular disease and protease inhibitors of the older generation are highlighted, in particular. АRT therapy in HIV-infected cells contributes to the development of a metabolic syndrome involving dyslipidemia, lipodystrophy and insulin resistance.



Arts, E.J., Hazuda, D.J. (2012) HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb Perspect Med, Apr; 2(4): a007161
Baker, J.V., Lundgren, J.D. (2011) Cardiovascular implications from untreated human immunodeficiency virus infection. European Heart Journal, 32(8): 945-951
Bavinger, C., Bendavid, E., Niehaus, K., Olshen, R.A., Olkin, I., Sundaram, V., Wein, N., Holodniy, M., Hou, N., Owens, D.K., Desai, M. (2013) Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: a Systematic Review. PLoS One, 8(3): e59551-e59551
Boccara, F., Lang, S., Meuleman, C., Ederhy, S., Marykrause, M., Costagliola, D. (2013) HIV and Coronary Heart Disease: Time for a better understanding. J Am Coll Cardiol, 61(5): 511-534
Boccara, F. (2008) Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: Type, incidence and associated risk factors. AIDS, 22(Suppl 3): S19-S26
Currier, J.S., Lundgren, J.D., Carr, A., Klein, D., Sabin, C.A., Sax, P.E., Schouten, J.T., Smieja, M. (2008) Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy. Circulation, 118(2): 29-35
Eugenin, E.A., Morgello, S., Klotman, M.E., Mosoian, A., Lento, P.A., i dr. (2008) Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: Implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol, 172(4): 1100-1111
Jevtović, D., Dragović, G., Salemović, D., Ranin, J., Djurković-Djaković, O. (2009) The metabolic syndrome: an epidemic among HIV-infected patients on HAART. Biomed Pharmacother, 63(5): 337-379
Lang, S., Boccara, F., Mary-Krause, M., Cohen, A. (2015) Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries. Archives of Cardiovascular Diseases, 108(3): 206-215
Quiros-Roldan, E., Magoni, M., Raffetti, E., Donato, F., Scarcella, C., Paraninfo, G., Castelli, F. (2016) The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population. BMC Public Health, 16(1): 1146-1146
Raposeiras-Roubín, S., Triant, V. (2016) Ischemic Heart Disease in HIV: an in-depth Look at Cardiovascular Risk. Revista Española de Cardiología (English Edition, 69(12): 1204-1213
Shlay, J.C., Bartsch, G., Peng, G., Wang, J., Grunfeld, C., Gibert, C.L., Visnegarwala, F., Raghavan, S.S., Xiang, Y., Farrough, M., Perry, H.E., Kotler, D., El-Sadr, W.M. (2007) Long-Term Body Composition and Metabolic Changes in Antiretroviral Naive Persons Randomized to Protease Inhibitor-, Nonnucleoside Reverse Transcriptase Inhibitor-, or Protease Inhibitor Plus Nonnucleoside Reverse Transcriptase Inhibitor-Based Strateg. JAIDS Journal of Acquired Immune Deficiency Syndromes, 44(5): 506-517
Volberding, P., Greene, W., Lange, J.M.A., Gallant, J.E., Sewankambo, N. (2013) Sande's HIV/AIDS Medicine: Medical Management of AIDS. Second Edition
Worm, S.W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., de Wit, S., Law, M., Monforte, A.D., Friis-Møller, N., Kirk, O., Fontas, E., Weller, I., Phillips, A., Lundgren, J. (2010) Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 201(3): 318-330